cardiovascular disease
cardiovascular disease
12/22/2022
In this article, James Matera, DO, writes about a newer agent, finarenone, which is a nonsteroidal, selective mineralocorticoid receptor antagonist that can treat chronic kidney disease.
12/22/2022
Commentary
Commentary
07/29/2022
In this flashback commentary, Dr James Matera from CentraState Medical Center reflects on a case report published in the 1990 issue of Consultant.
07/29/2022
Nutrition
Dr. James Matera
Nutrition
02/13/2022
In this commentary, Dr James Matera, from CentraState Medical Center, discusses new research on the effects of fruit and vegetable intake on mortality in patients undergoing hemodialysis.
02/13/2022
Treatment
Treatment
11/12/2021
In this article, James Matera, DO, writes about the benefits of using SGLT2 inhibitors to treat patients with type 2 diabetes, chronic kidney disease, and cardiovascular disease, including how the use of...
11/12/2021
Management
Management
04/20/2021
In this article, James Matera, DO, talks about the importance of evaluating a patient’s estimated glomerular filtration rate and how an eGFR compares with actual GFR.
04/20/2021
adrenal insufficiency
adrenal insufficiency
02/02/2021
In this commentary, James Matera, DO, writes about the ESRD treatment choice model that started on January 1, 2021, as well as its importance to and implications for practitioners.
02/02/2021
Top Papers Of The Month
Top Papers Of The Month
01/13/2021
In this Top Papers column, James Matera, DO, writes about 3 important research papers that highlight new potential treatment options for patients with CKD and anemia, and those with CKD and cardiovascular...
01/13/2021